BioTuesdays
Medicinova inc logo

Maxim starts MediciNova at buy; PT $15

Maxim Group launched coverage of MediciNova (NASDAQ:MNOV) with a “buy” rating and $15 price target. The stock closed at $5.68 on March 9. MediciNova is developing MN-166 for neurodegenerative diseases, glioblastoma...

PhaseBio Pharmaceuticals

PhaseBio discontinues Phase 2 COVID-19 trial

PhaseBio Pharmaceuticals (NASDAQ:PHAS) discontinued its Phase 2 trial evaluating PB1046 for the treatment of high-risk, hospitalized COVID-19 patients. PB1046 is a long-acting analog of vasoactive intestinal peptide...

iBio Inc. Logo

iBio featured on ABC affiliate

KXXV, an ABC affiliate in Bryan, Texas, published an article on iBio’s (NYSE AMERICAN:IBIO) two COVID-19 vaccine candidates.  The company recently reported that it has selected IBIO-201 as its leading candidate for...